The bleeding time: its potential utility among patients receiving thrombolytic therapy

Area of Science:

• Hematology
• Clinical Pathology

Background:

• The bleeding time (BT) test, established 80 years ago, has historically been viewed as a rudimentary and time-consuming diagnostic tool.
• Despite its limitations, technical advancements and standardization have enhanced the BT's reliability, prompting its consideration for preoperative screening.
• Its clinical application has remained limited, primarily to neurosurgery and organ biopsy procedures.

Purpose of the Study:

• To explore the renewed interest in the BT test for patients receiving thrombolytic therapy.
• To investigate the BT's utility in predicting hemorrhagic complications, as fibrinogen and fibrin degradation products have shown limited predictive value.
• To examine the potential impact of thrombolysis on platelet function and its manifestation as prolonged BT.

Main Methods:

• Review of historical and current applications of the bleeding time test.
• Analysis of the rationale for using BT in patients undergoing thrombolytic therapy.
• Proposed research to investigate BT prolongation and its correlation with hemorrhagic complications.

Main Results:

• Thrombolytic therapy may impair platelet function through granule depletion or direct proteolytic effects.
• The BT test is being considered as a potential predictor of hemorrhagic complications in this patient group.
• Further research is needed to validate these findings.

Conclusions:

• The BT test shows promise as a valuable tool for assessing bleeding risk in patients receiving thrombolytic therapy.
• Investigating BT prolongation could offer a more reliable method for identifying patients at risk for bleeding complications.
• Prospective studies are required to confirm the BT's efficacy in clinical practice.